戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1      Immune suppression poses a challenge to vaccine immunogenicity.
2 tly with rotavirus vaccine reduced rotavirus vaccine immunogenicity.
3 as 10 weeks' replacement enhances humoral HZ vaccine immunogenicity.
4 ine administration can significantly enhance vaccine immunogenicity.
5 ic and specific effects of diet on influenza vaccine immunogenicity.
6 e is a significant regulator of nucleic acid vaccine immunogenicity.
7 diseases, but subclinical malaria may reduce vaccine immunogenicity.
8 A remains a critically useful measurement of vaccine immunogenicity.
9 re influenza infection because of suboptimal vaccine immunogenicity.
10 echanisms that may be manipulated to enhance vaccine immunogenicity.
11 er antibiotics would improve oral poliovirus vaccine immunogenicity.
12 le of macrophages as mediators of RABV-based vaccine immunogenicity.
13 immunomodulating impact of H. pylori on oral vaccine immunogenicity.
14 abies vaccine was shown to result in reduced vaccine immunogenicity.
15 s is likely to be an important attribute for vaccine immunogenicity.
16 these mutations to virulence attenuation and vaccine immunogenicity.
17  to optimize this regimen to further augment vaccine immunogenicity.
18 g specific antibody sequences as measures of vaccine immunogenicity.
19 f evaluating the naive repertoire to predict vaccine immunogenicity.
20 mplified vaccination logistics and increased vaccine immunogenicity.
21 to boost immune function to enhance anti-HIV vaccine immunogenicity.
22 ted only minimal suppressive effects on rAd5 vaccine immunogenicity.
23 in the evaluation of disease pathogenesis or vaccine immunogenicity.
24  observed, but were insufficient to suppress vaccine immunogenicity.
25 n is a critical rate-limiting factor for DNA vaccine immunogenicity.
26 he MHC class II cytoplasmic domain abrogates vaccine immunogenicity.
27 s additional studies designed to enhance DNA vaccine immunogenicity.
28 cell responses yields critical insights into vaccine immunogenicity.
29 ay can affect assessments of human norovirus vaccine immunogenicity.
30 "hybrid immunity") may clarify predictors of vaccine immunogenicity.
31 ygiene (WASH) may contribute to reduced oral vaccine immunogenicity.
32       CpGs therefore can efficiently improve vaccines' immunogenicity.
33 or quantitative evaluation of the SARS-CoV-2 vaccines' immunogenicity.
34 ally active lifestyle may enhance SARS-CoV-2 vaccine immunogenicity, a finding of particular clinical
35  transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovir
36 cellular immunity in SOTRs to track COVID-19 vaccine immunogenicity against emerging variants.
37  being focused on adjuvants that can broaden vaccine immunogenicity against emerging viruses and maxi
38 pe challenge studies to preliminarily assess vaccine immunogenicity against influenza, shigellosis, c
39                                      Data on vaccine immunogenicity against SARS-CoV-2 are needed for
40 NA delivery to cells, and finally intranasal vaccine immunogenicity, allowing for identification of a
41 investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseas
42 D4(+) T cells in blood is an early marker of vaccine immunogenicity and an important immune parameter
43                        Rationale: Suboptimal vaccine immunogenicity and antigenic mismatch, compounde
44                                              Vaccine immunogenicity and antitumor potency were enhanc
45 ng antibody titers are a critical measure of vaccine immunogenicity and are used to determine flavivi
46                                              Vaccine immunogenicity and effectiveness vary geographic
47 s in comparison with adults, (2) the data on vaccine immunogenicity and efficacy in children, and (3)
48 ory vaccine adjuvant may influence RhCMV/SIV vaccine immunogenicity and efficacy.
49  in rhesus macaques, commonly used to assess vaccine immunogenicity and efficacy.
50  the lack of human in vitro models to assess vaccine immunogenicity and efficacy.
51 reatment for acute COVID-19, and interrogate vaccine immunogenicity and performance in preclinical, c
52  the effects of comorbid T2DM and obesity on vaccine immunogenicity and protection.
53 use trials in high-income settings differ in vaccine immunogenicity and schedules from other settings
54 orage of rPA vaccines would adversely affect vaccine immunogenicity and therefore the storage life of
55 many factors have the potential to influence vaccine immunogenicity and therefore vaccine effectivene
56 e and host genetics may significantly impact vaccine immunogenicity and/or efficacy, whether LPS is a
57 r understanding of the relationships between vaccine, immunogenicity and protection from disease woul
58  severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic
59                              Here, we assess vaccine immunogenicity beyond neutralizing function, inc
60 ked to severe influenza illness and impaired vaccine immunogenicity, but the relationship between BMI
61               Adjuvants such as AS03 improve vaccine immunogenicity, but this mechanism is poorly und
62 n represents a promising strategy to augment vaccine immunogenicity by targeting Ag to mannose recept
63           Optimizing these factors increases vaccine immunogenicity by up to 90-fold and maximizes th
64                                  To evaluate vaccine immunogenicity, children who had received the re
65 ministration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle
66 during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).
67                             Quadrivalent HPV vaccine immunogenicity delivered on 3 alternative dosing
68      These results reinforce the notion that vaccine immunogenicity does not predict control of AIDS
69 posal, and offer the possibility of improved vaccine immunogenicity, dose sparing and thermostability
70 belimumab treatment was associated with poor vaccine immunogenicity due to inhibition of naive B cell
71        Human studies that reported influenza vaccine immunogenicity, effectiveness, and efficacy were
72 regarding measles seroprevalence and measles vaccine immunogenicity, efficacy, and safety in HIV-infe
73 ly used as the gold standard for determining vaccine immunogenicity, even though their role in cleara
74 sociated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cel
75 ore, an insight is provided to the impact on vaccine immunogenicity from altering vaccination methods
76        The potential effect of fH binding on vaccine immunogenicity had not been assessed in experime
77                                          DNA vaccine immunogenicity has been limited by inefficient d
78                                              Vaccine immunogenicity has dramatically improved in a ce
79             For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined b
80 ctors associated with pneumococcal conjugate vaccine immunogenicity have not been explored.
81 y, we find that DCs are essential for MHC II vaccine immunogenicity; however, they mediate their effe
82         Herein we review the current data on vaccine immunogenicity in cancer patients, including rec
83 ses, making this a new possible indicator of vaccine immunogenicity in children.
84  should be evaluated for improving rotavirus vaccine immunogenicity in high burden countries.
85 mitant receipt of OPV, that affect rotavirus vaccine immunogenicity in high- and low-child-mortality
86 xplored as a potential method to enhance DNA vaccine immunogenicity in humans.
87 :alum immunizations synergistically enhanced vaccine immunogenicity in mice and rhesus macaques, indu
88 ptide epitopes to carrier proteins optimizes vaccine immunogenicity in mice.
89  evidence for the importance of autophagy in vaccine immunogenicity in older humans and uncovered two
90                           Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited.
91 nant protein boost would impact HIV-specific vaccine immunogenicity in rhesus macaques (RhM).
92 nts and report on the secondary objective of vaccine immunogenicity in the full cohort of people livi
93 odominant regions should improve the overall vaccine immunogenicity in the local population and minim
94 el for preclinical vaccine testing; however, vaccine immunogenicity in these models often inadequatel
95 lly, we investigated potential predictors of vaccine immunogenicity, including age group and CD4/CD8
96 e development of novel adjuvants to increase vaccine immunogenicity is an important goal that seeks t
97                                 Furthermore, vaccine immunogenicity is frequently suboptimal in the v
98 tion; however, a comprehensive assessment of vaccine immunogenicity is lacking.
99                                              Vaccine immunogenicity is reduced in kidney transplant r
100                                    Influenza vaccine immunogenicity is suboptimal in immunocompromise
101 few patients with kidney disease; therefore, vaccine immunogenicity is uncertain in this population.
102 er replacement of MMF by everolimus improves vaccine immunogenicity is unknown.
103                   While the effect of RNA on vaccine immunogenicity is well studied, the role of biom
104 However, standard assays of experimental HIV vaccine immunogenicity may not correlate with antiviral
105                                  To increase vaccine immunogenicity, modern vaccines incorporate adju
106 and characterized the protein expression and vaccine immunogenicity of both platforms.
107 cular versus intranasal) of LNP impacted the vaccine immunogenicity of two model antigens (influenza
108                        Only those addressing vaccine immunogenicity or efficacy of preventative vacci
109 tigens has the potential to adversely affect vaccine immunogenicity over time.
110 obably affected by the lower oral poliovirus vaccine immunogenicity previously demonstrated in resour
111        Existing methods to measure influenza vaccine immunogenicity prohibit detailed analysis of epi
112                The treatment did not augment vaccine immunogenicity; rather, it dramatically increase
113                                  We assessed vaccine immunogenicity, safety, and three primary outcom
114 odeling the effects of metabolic diseases on vaccine immunogenicity that is essential for the develop
115 NA vaccine-induced pyroptotic cell death and vaccine immunogenicity that is instrumental in shaping t
116 magnitude, these results offer insights into vaccine immunogenicity variations that may help inform v
117 piratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and i
118 ryotic RNA encapsulated within VLP Peanut on vaccine immunogenicity was assessed by producing a VLP P
119                  The Flt3L-Fc enhancement in vaccine immunogenicity was comparable to a combination w
120                                              Vaccine immunogenicity was demonstrated in mice with pot
121                                              Vaccine immunogenicity was measured by hemagglutination-
122                                              Vaccine immunogenicity was measured by hemagglutination-
123 n mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantit
124  of new-generation anthrax vaccines--affects vaccine immunogenicity, we created a "genetically deamid
125                                   To improve vaccine immunogenicity, we incorporated CD40 ligand (CD4
126 us in KTRs does not improve COVID-19 booster vaccine immunogenicity, whereas 10 weeks' replacement en
127 es the best example of a gradual decrease of vaccine immunogenicity with every 10-year age increase a
128 nd effective cross-species method to improve vaccine immunogenicity with potentially broad applicabil

 
Page Top